Tianjin Meihua biomedical technology Co.,Ltd.

Primary objective: To evaluate whether the test preparation Roxithromycin Dispersible Tablets produced by Tianjin Meihua Biopharmaceutical Technology Co., Ltd. and the reference preparation Roxithromycin Tablets (Rolide®) produced by Opella Healthcare International SAS are bioequivalent after oral administration in healthy subjects in the fasting state. Secondary objective: To observe the safety of the test preparation Roxithromycin Dispersible Tablets and the reference preparation Roxithromycin Tablets (Rolide®) in healthy subjects.

A single-center, randomized, open, two-period, two-sequence, double-crossover, single-dose oral trial design was used to compare the differences in absorption extent and absorption rate between venlafaxine hydrochloride sustained-release capsules (75 mg) produced by Tianjin Meihua Biomedical Technology Co., Ltd. and venlafaxine hydrochloride sustained-release capsules (trade name: EFFEXOR XR®/Effexor®; specification: 75 mg) licensed by Pfizer Healthcare Ireland in healthy Chinese people under the condition of postprandial administration, and to evaluate the safety of venlafaxine hydrochloride sustained-release capsules produced by Tianjin Meihua Biomedical Technology Co., Ltd.

Primary objective: To evaluate whether the test preparation indapamide sustained-release tablets (specification: 1.5 mg) produced by Tianjin Meihua Biopharmaceutical Technology Co., Ltd. and the reference preparation indapamide sustained-release tablets (trade name: Natali®, specification 1.5 mg) produced by Servier (Tianjin) Pharmaceutical Co., Ltd. are bioequivalent after oral administration in healthy subjects in fasting and postprandial states. Secondary objective: To observe the safety of the test preparation indapamide sustained-release tablets and the reference preparation indapamide sustained-release tablets in healthy subjects.